Abstract:Asian indices are looking to open soft in Thursday’s session after major US Indices extended their sell-off in Wednesdays session on stronger than expected US data and a “hawkish” FOMC minutes where Fed officials saw ‘upside risks’ to inflation possibly leading to more rate hikes.

Asian indices are looking to open soft in Thursday‘s session after major US Indices extended their sell-off in Wednesdays session on stronger than expected US data and a “hawkish” FOMC minutes where Fed officials saw ’upside risks‘ to inflation possibly leading to more rate hikes. The Russell 2000 led losses (-1.28%) in the US on the continued underperformance of regional banks, though the risk sensitive Nasdaq (-1.15%) wasn’t far behind in a broad-based sell-off.

FX Markets
A jump in US treasury yields, which saw the US 10 year pushing higher above its 4% resistance level, and a risk off tone in the market saw the USD surge higher again, DXY testing and holding the big 103 level and pushing up to test cycle highs resistance at 103.55. Strong US data (Industrial Production smashing expectations) and the aforementioned FOMC minutes also being strong tailwinds for the USD.
JPY was markedly weaker on a perfect storm of rising US10 and JP10 yield differentials and a rampant USD. USDJPY hit a high of 146.38, well into the “intervention zone” where the BoJ entered the market to strengthen the Yen late last year. There is Japanese CPI data on Friday, but my feeling is nothing short of robust BoJ action will reverse this grind higher in USDJPY.

AUD and NZD were softer against the USD weighed down by the risk-off market tone and concerns about Chinas economic recovery. The Kiwi did outperformed the Aussie after Yesterdays RBNZ rate decision where they kept rates on hold but gave what was seen as hawkish forward guidance, this saw AUDNZD push down to test the big figure at 1.08 before finding some support. AUD traders have a pivotal employment report to look forward to today at 11:30 AEST

Gold continued its month-long downtrend, higher yields and a strong USD weighing heavily on the precious metal, with haven flows seeing to go anywhere but to Gold at the moment. XAUUSD pushing below its support level at 1903 USD an ounce and hitting lows not seen since March.
Todays calendar is fairly light with the major risk events being jobs data out of Australia and the US later in the session.



Have you had to encounter numerous denials on fund withdrawals by KapitalRS, a Serbia-based CFD broker? Were you asked to pay additional fees for withdrawal access? Did you incur losses on your forex positions due to the confusion concerning the bonus? Does your overall trading cost go up due to the wide spreads charged by the forex broker? These issues have arguably become the highlight on several broker review platforms. In this KapitalRS article, we have elaborated on numerous complaints against the brokerage firm. Take a look!

Trive, a Netherlands-based leading CFD broker across forex, stocks, indices and commodities, is facing ire from its employees on the unpaid salary crisis that has haunted them for four months starting from November 2025. Upset over such a long delay, employees have been using social media platforms to express their frustration. Read on for more revelation.

Did you have a good trading experience with LONG ASIA initially before it went bad, as you sought fund withdrawals from the platform? Did Saint Vincent and the Grenadines-based forex brokerage house deny you access to funds despite numerous withdrawal requests? Have you lost your funds because of this denial? Failing to log in despite numerous attempts? You are not alone! Many traders have accused the broker of these trading practices. In this LONG ASIA review article, we have highlighted some complaints against the broker. Read on as we share all these details with you.

The Financial Industry Regulatory Authority (FINRA) has filed a formal complaint against Spartan Capital Securities LLC, its CEO John Dennis Lowry, and its former Chief Compliance Officer (CCO) Kim Marie Monchik. The Department of Enforcement alleges a sophisticated scheme to defraud customers during a pharmaceutical company’s initial public offering (IPO), resulting in over $50 million in profits for the firm and its insiders while customers were left with dramatic losses.